Nan Lin

Dr. Nan Lin


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
ZYZhicheng Yao
Zhicheng Yao
CDCao Dai
Cao Dai
JYJiawei Yang
Jiawei Yang
MXMingxing Xu
Mingxing Xu
HMHongyu Meng
Hongyu Meng
NLNan Lin
Nan Lin
Background: A previous study has examined the overall cancer statistics. However, more detailed statistics regarding liver cancer have not been provided. We evaluated the incidence and mortality trends of liver and intrahepatic bile duct cancer in the United States from 1975 to 2017 based on the data in the Surveillance, Epidemiology, and End Results (SEER) database. Methods: Age, gender, race, metastasis, tumor site, and tumor grade of patients were extracted from the SEER database. Codes C22.0 and C22.1 of the International Classification of Disease for Oncology were applied to identify patients with hepatocellular carcinoma (HCC) and/or intrahepatic cholangiocarcinoma (ICC). Age-specified incidence, age-standardized incidence and mortality, 5-year relative survival, race-specific accumulative incidence and mortality, and geographic-specific accumulative mortality were calculated in different groups. Changes in trends of liver cancer incidence and mortality were assessed using Joinpoint regression. Results: The overall incidence increased significantly from 2.641/100,000 person-years in 1975 to 8.657/100,000 person-years in 2017 [average annual percent change (AAPC) =3.42, 95% confidence interval (CI): 3.28–3.62, P<0.001]. The steepest incidence rate increase was observed in the 60–69-year-old age group (AAPC =4.40, 95% CI: 4.10–4.70, P<0.001). Males exhibited a more rapid increase in cancer incidence, from 3.928/100,000 to 13.128/100,000 person-years (AAPC =3.41, 95% CI: 3.21–3.61, P<0.001), than females [from 1.642/100,000 to 4.783/100,000 person-years (AAPC =3.03, 95% CI: 2.91–3.21, P=0.001)]. The overall mortality rate increased from 2.808/100,000 person-years in 1975 to 6.648/100,000 person-years in 2017 (AAPC =2.41, 95% CI: 2.29–2.51, P<0.001). The highest mortality rate was observed in Hawaii (6.996/100,000 person-years). Conclusions: The incidence and mortality rates of HCC and ICC increased from 1975 to 2017, especially in males, non-Hispanic Blacks and older individuals. Comprehensive policy and control measures should be implemented to reduce the burden of disease, particularly through health monitoring and intervention for high-risk groups.

13 January 2025 in ACS Omega
Verified
Journal Article
Open access
YFYuan Feng
Yuan Feng
BLBin Lu
Bin Lu
YHYongheng Huang
Yongheng Huang
HWHui Wang
Hui Wang
JXJianliang Xu
Jianliang Xu
NLNan Lin
Nan Lin
Perfluorooctanoic acid (PFOA), a typical environmental contaminant, has been observed in tissue samples of various diseases, including liver cancer. PFOA can lead to hepatotoxicity, but the underlying molecular mechanism remains unclear. Our results showed that PFOA significantly inhibited HL-7702 (L02) and MIHA cell viability in a time- and dose-dependent manner. Furthermore, PFOA could cause oxidative stress, mitochondrial injury, and ferroptosis. In addition, PFOA upregulated the levels of malondialdehyde and glutathione/oxidized glutathione and downregulated the expressions of SLC7A11 and GPX4, which refer to typical phenotypes of ferroptosis. PFOA suppressed phosphorylation of signaling cascades AKT/GSK3β/β-catenin, indicating the signal pathway might be related to ferroptosis. In order to prove the above hypothesis, the Wnt signaling pathway activator chir99021 was used and the result revealed that PFOA-induced inhibition of p-AKT and its downstream effectors p-GSK3β, SLC7A11, and GPX4 was counteracted. On the other hand, the inhibitor of p-AKT, Ly294002, strengthened PFOA's regulatory actions on these factors. Overall, our results suggest that PFOA can lead to liver cell injury by inducing oxidative stress and ferroptosis. The effects are conferred through the regulation of the AKT/GSK3β/β-catenin signaling cascades.

28 July 2022 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
YFYuan Feng
Yuan Feng
YLYanjie Li
Yanjie Li
MXMingxing Xu
Mingxing Xu
HMHongyu Meng
Hongyu Meng
CDCao Dai
Cao Dai
NLNan Lin
Nan Lin
Background: The mechanism of bone marrow mesenchymal stem cells (BMSCs) in treating hepatic fibrosis remains unclear. Methods: TGF-β1-induced hepatic stellate cell (HSC)-T6 and CCl4-induced hepatic fibrosis rats were treated with BMSCs. HSC-T6 cell activity was determined using the cell counting kit-8 assay, and the histology change was evaluated using hematoxylin and eosin and Masson staining. The expression of fibrosis markers was determined using real-time quantitative PCR, Western blotting, and immunocytochemistry. RNA sequencing (RNA-seq) was used to screen the lncRNAs involved in the effect of BMSCs in fibrosis, and the function of fibrosis-associated lncRNA in fibrosis histology change and fibrosis marker expression was investigated. The potential miRNA target of lncRNA was predicted using R software. The interaction between lncRNA and miRNA was verified using luciferase report system and RNA immunoprecipitation (RIP) in 293T and HSC-T6 cells. Results: BMSC attenuated TGF-β1-induced HSC-T6 activation and suppressed the expression of fibrosis-associated gene (MMP2, Collagen I, and αSMA) expression at the transcription and translation levels. BMSC treatment also improves hepatic fibrosis in rats with CCl4-induced fibrosis by decreasing the expression of fibrosis-associated genes and suppressing collagen deposition in the liver. RNA-seq revealed that AABR07028795.2 (lnc-BIHAA1) was downregulated in the TGF-β1-induced HSC-T6 after treatment with BMSCs as compared with those in TGF-β1-induced HSC-T6, and subsequently, functional analysis showed that lnc-BIHAA1 plays a beneficial role in suppressing hepatic fibrosis. Luciferase activity assay and RIP revealed that lnc-BIHAA1 interacted with the miRNA, rno-miR-667-5p, functioning as a fibrosis phenotype suppressor in TGF-β1-induced HSC-T6. Moreover, overexpression of rno-miR-667-5p significantly reverses the effect of lnc-BIHAA1 on HSC-T6. Conclusions: BMSC treatment suppresses hepatic fibrosis by downregulating the lnc-BIHAA1/rno-miR-667-5p signaling pathway in HSCs. Our results provide a scientific basis for establishing BMSCs as a biological treatment method for liver fibrosis.

23 July 2021 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
RWRixiong Wang
Rixiong Wang
NLNan Lin
Nan Lin
BMBinbin Mao
Binbin Mao
QWQing Wu
Qing Wu

1 February 2021 in Aging
Verified
Journal Article
Open access
MXMingxing Xu
Mingxing Xu
HLHao Liang
Hao Liang
KLKun Li
Kun Li
SZShu Zhu
Shu Zhu
ZYZhicheng Yao
Zhicheng Yao
NLNan Lin
Nan Lin
It is important to identify novel biomarkers to improve hepatocellular carcinoma (HCC) diagnosis and treatment. Herein, we reported the role of karyopherin α4 (KPNA4) in HCC patients through public data mining and examined the results using clinical samples in our center. Our results revealed that KPNA4 expression level was positively correlated with the infiltration of CD8+ T cells, B cells, dendritic cells, CD4+ T cells, neutrophils and macrophages. In addition, KPNA4 expression was significantly associated with T cell exhaustion. KPNA4 mRNA and protein expression levels were significantly higher in cancerous tissue than in normal tissue. Besides, the increased expression of KPNA4 indicated poor overall survival. Univariate and multivariate Cox regression analyses showed KPNA4 could be viewed as an independent risk factor for HCC patients. Moreover, our experimental results were consistent with those obtained from bioinformatic results. These findings revealed KPNA4 may serve as a novel prognostic biomarker and a potential therapeutic target for HCC.

1 March 2019 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MXMingxing Xu
Mingxing Xu
ZZZheng Zhou
Zheng Zhou
RXRuiyun Xu
Ruiyun Xu
HZHuiling Zhang
Huiling Zhang
NLNan Lin
Nan Lin
YZYuesi Zhong
Yuesi Zhong
The effect of antiviral therapy (AVT) on clinical outcomes in patients with hepatocellular carcinoma (HCC) who are seronegative for hepatitis B virus (HBV), defined as HBV DNA < 100 IU/ml prior to surgical resection, is unknown. The main purpose of this study was to evaluate the possible value of AVT in this cohort of patients. From January 2006 to January 2013, 161 HCC patients with positive serum tests for HBV surface antigen (HBsAg) but negative tests for HBV DNA who had undergone hepatectomy were included and analyzed. Propensity score matching (PSM) was used to balance the heterogeneity in baseline characteristics. All patients were divided into the following two groups: the AVT group (n = 73, 45.34%) and the non-AVT group (n = 88, 54.66%). HBV reactivation occurred in 20 patients in the non-AVT group (22.73%) but in only 2 patients in the AVT group (2.74%, p < 0.001). After PSM, the 1-, 2-, and 3-year recurrence-free survival (RFS) rates in the AVT group and the non-AVT group were 78.38%, 72.97%, and 62.16% and 81.08%, 72.97%, and 72.97%, respectively (p = 0.564); the 1-, 2-, and 3-year overall survival (OS) rates were 97.30%, 97.3%, and 91.89% and 94.59%, 94.59%, and 86.49% in the AVT group and non-AVT group, respectively (p = 0.447). Antiviral therapy can reduce HBV reactivation but is not correlated with a significant increase in postoperative RFS and OS in HCC patients with HBV DNA levels < 100 IU/ml.